G1 Therapeutics: Funding, Investors & Team (Aug 2026)
G1 Therapeutics, Inc. is a biopharmaceutical business at the commercial stage that focuses on the discovery, development, and delivery of novel therapeutics to help people with cancer live better lives. One of the company's first commercial products is COSELATM (Trilaciclib) G1 is advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer, as well as having a robust clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. 2020 will mark the year that G1 outlicenses the rights to its distinct oral CDK4/6 inhibitor, lerociclib, for worldwide development and commercialization. North Carolina's Research Triangle Park is home to G1 Therapeutics. Visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics for more information.
G1 Therapeutics has raised $50.1M across 1 funding round on record, the most recent an undisclosed round of $50.1M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
G1 Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2022.
G1 Therapeutics Funding Rounds
G1 Therapeutics Founders and Leadership Team
Contact details for the G1 Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →G1 Therapeutics Funding Compared to Other Biotechnology Startups
G1 Therapeutics' latest round of $50.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like G1 Therapeutics in Biotechnology and Durham
Companies Similar to G1 Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
G1 Therapeutics Funding FAQs
What does G1 Therapeutics do?
G1 Therapeutics, Inc. is a biopharmaceutical business at the commercial stage that focuses on the discovery, development, and delivery of novel therapeutics to help people with cancer live better lives. One of the company's first commercial products is COSELATM (Trilaciclib) G1 is advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer, as well as having a robust clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. 2020 will mark the year that G1 outlicenses the rights to its distinct oral CDK4/6 inhibitor, lerociclib, for worldwide development and commercialization. North Carolina's Research Triangle Park is home to G1 Therapeutics. Visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics for more information.
How much funding has G1 Therapeutics raised?
G1 Therapeutics has raised $50.1M across 1 round on record. The most recent is an undisclosed round of $50.1M announced in Nov 2022.
When did G1 Therapeutics last raise funding?
G1 Therapeutics' most recent funding round on record is an undisclosed round of $50.1M, announced in Nov 2022.
Who is the CEO of G1 Therapeutics?
Jack Bailey is listed as CEO at G1 Therapeutics.
Where is G1 Therapeutics headquartered?
G1 Therapeutics is based in Durham, North Carolina, United States.
How many employees does G1 Therapeutics have?
G1 Therapeutics is in the 101-250 employee band.
How does G1 Therapeutics' funding compare to other Biotechnology startups?
G1 Therapeutics' latest round of $50.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's G1 Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for G1 Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.